Total Payments
$51,942
2024 Payments
$3,653
Companies
21
Transactions
89
Medicare Patients
582
Medicare Billing
$70,345
Payment Breakdown by Category
Consulting$41,493 (79.9%)
Travel$5,452 (10.5%)
Food & Beverage$3,806 (7.3%)
Other$1,186 (2.3%)
Education$5.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $41,493 | 11 | 79.9% |
| Travel and Lodging | $5,452 | 21 | 10.5% |
| Food and Beverage | $3,806 | 54 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,186 | 2 | 2.3% |
| Education | $5.56 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $15,483 | 15 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $9,726 | 16 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $6,280 | 7 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $5,262 | 14 | $0 (2018) |
| Genentech, Inc. | $4,889 | 5 | $0 (2018) |
| Genmab U.S., Inc. | $3,593 | 2 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,209 | 4 | $0 (2019) |
| Lilly USA, LLC | $1,749 | 2 | $0 (2017) |
| Incyte Corporation | $1,360 | 5 | $0 (2019) |
| Exelixis Inc. | $300.71 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,653 | 3 | Genmab U.S., Inc. ($3,593) |
| 2023 | $175.54 | 2 | Coherus Biosciences Inc. ($115.54) |
| 2022 | $138.68 | 1 | Seagen Inc. ($138.68) |
| 2019 | $5,103 | 11 | Merck Sharp & Dohme Corporation ($2,883) |
| 2018 | $17,774 | 30 | Genentech USA, Inc. ($9,191) |
| 2017 | $25,098 | 42 | Genentech USA, Inc. ($6,292) |
All Payment Transactions
89 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/15/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $3,532.50 | General |
| Category: Oncology | ||||||
| 09/15/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $60.34 | General |
| Category: Oncology | ||||||
| 07/27/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $115.54 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 06/03/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 06/04/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $138.68 | General |
| 06/12/2019 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Consulting Fee | Cash or cash equivalent | $2,060.00 | General |
| Category: Oncology | ||||||
| 06/12/2019 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Food and Beverage | In-kind items and services | $124.21 | General |
| Category: Oncology | ||||||
| 06/12/2019 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Travel and Lodging | Cash or cash equivalent | $8.21 | General |
| Category: Oncology | ||||||
| 02/22/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 02/22/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 02/17/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $364.70 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $48.66 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: ONCOLOGY | ||||||
| 02/16/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $231.74 | General |
| Category: ONCOLOGY | ||||||
| 02/16/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $27.48 | General |
| 10/21/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $46.76 | General |
| Category: BioOncology | ||||||
| 09/24/2018 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $606.00 | General |
| 08/01/2018 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| 08/01/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 07/27/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $38.26 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $227.00 | General |
| 07/20/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 07/20/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $39.85 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 134 | 189 | $102,681 | $15,557 |
| 2022 | 5 | 160 | 240 | $122,738 | $19,230 |
| 2021 | 4 | 159 | 262 | $124,339 | $23,098 |
| 2020 | 5 | 129 | 173 | $68,831 | $12,461 |
Total Patients
582
Total Services
864
Medicare Billing
$70,345
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 76 | 126 | $63,252 | $9,316 | 14.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $20,448 | $3,221 | 15.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 14 | 15 | $10,485 | $1,792 | 17.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 20 | 24 | $8,496 | $1,229 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 82 | 152 | $74,192 | $11,618 | 15.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 17 | 17 | $14,156 | $2,448 | 17.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 19 | $12,873 | $1,951 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 31 | 39 | $13,398 | $1,875 | 14.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 13 | 13 | $8,119 | $1,338 | 16.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 80 | 167 | $72,926 | $13,068 | 17.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 39 | $23,185 | $4,676 | 20.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $17,933 | $3,558 | 19.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 27 | 33 | $10,295 | $1,797 | 17.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 65 | 103 | $36,965 | $6,438 | 17.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $11,201 | $2,271 | 20.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 16 | 18 | $8,360 | $1,603 | 19.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $6,616 | $1,198 | 18.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 19 | 23 | $5,689 | $950.87 | 16.7% |
About Dr. Primo Lara, M.D
Dr. Primo Lara, M.D is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972585743.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Primo Lara, M.D has received a total of $51,942 in payments from pharmaceutical and medical device companies, with $3,653 received in 2024. These payments were reported across 89 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($41,493).
As a Medicare-enrolled provider, Lara has provided services to 582 Medicare beneficiaries, totaling 864 services with total Medicare billing of $70,345. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Sacramento, CA
- Active Since 11/17/2005
- Last Updated 09/16/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1972585743
Products in Payments
- TECENTRIQ (Biological) $16,272
- IMFINZI (Drug) $6,206
- Alecensa (Biological) $4,100
- Epkinly (Drug) $3,593
- Erleada (Drug) $2,192
- KEYTRUDA (Biological) $733.10
- Cabometyx (Drug) $300.71
- MEKINIST (Drug) $162.44
- XTANDI (Drug) $152.00
- Udenyca (Biological) $115.54
- PADCEV (Biological) $60.34
- Padcev (Drug) $60.00
- Rubraca (Drug) $60.00
- VOTRIENT (Drug) $23.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Dr. Scott Christensen, M.d, M.D
Hematology & Oncology — Payments: $391,606
Hematology & Oncology $391,606
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Paul Kaesberg, M.d, M.D
Hematology & Oncology — Payments: $221,939
Hematology & Oncology $221,939